Piperazinyl derivatives as modulators of chemokine receptor...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S255010, C544S360000, C544S365000, C544S384000, C544S386000, C544S391000

Reexamination Certificate

active

07615556

ABSTRACT:
The present application describes modulators of MIP-1α of formula (I):or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R1, R4, R5, R5aand R5bare as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

REFERENCES:
patent: 5847148 (1998-12-01), Jacobsen et al.
patent: 6391865 (2002-05-01), Baroudy et al.
patent: 2003/0162764 (2003-08-01), Castelhano et al.
patent: 2003/0229067 (2003-12-01), Castelhano et al.
patent: 4243858 (1994-06-01), None
patent: 0771565 (1997-05-01), None
patent: 0838460 (1998-04-01), None
patent: 2001/354657 (2000-12-01), None
patent: 2001-354657 (2001-12-01), None
patent: WO 92/15304 (1992-09-01), None
patent: WO 94/25437 (1994-11-01), None
patent: WO 95/34311 (1995-12-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 98/17625 (1998-04-01), None
patent: WO 99/08697 (1999-02-01), None
patent: WO 99/08699 (1999-02-01), None
patent: 99/11657 (1999-03-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 03/007949 (2003-01-01), None
patent: WO 03/009847 (2003-02-01), None
patent: WO 03/022835 (2003-03-01), None
patent: WO 03/092688 (2003-11-01), None
patent: WO 2004/037796 (2004-05-01), None
patent: WO 2004/076418 (2004-09-01), None
patent: WO 2004/113323 (2004-12-01), None
patent: WO 2005/003127 (2005-01-01), None
patent: WO 2005/056015 (2005-06-01), None
patent: WO 2005/118579 (2005-12-01), None
patent: WO 2006/013073 (2006-02-01), None
Baraldi, P. et al., “Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7receptor”, J. Med. Chem., vol. 46, pp. 1318-1320 (2003).
Carson, K. et al., “CCR1 Antagonists”, Annual Reports in Medicinal Chemistry, vol. 39, pp. 149-158 (2004).
Lang, L. et al., (Database Beilstein, Beilstein Institute for Organic Chemistry, BRN#: 8854794), J. Labelled Compd. Radiopharm., vol. 44, pp. S21-S23 (2001).
Oshiro, Y. et al., “Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives”, J. Med. Chem., vol. 34, No. 7, pp. 2014-2023 (1991).
Pessoa-Mahana, H. et al., “Synthesis of 4-arylpiperazine derivatives of moclobemide: Potential antidepressants with a dual mode of action”, Synthetic Communications, vol. 34, No. 14, pp. 2513-2521 (2004).
Richardson, T. et al., “Synthesis and structure -activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor”, J. Med. Chem., vol. 47, pp. 744-755 (2004).
Tiwari, M., (Database Beilstein, Beilstein Institute for Organic Chemistry, BRN#: 943608, 944316), J. Indian Chem. Soc., vol. 53, pp. 310-311 (1976).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Piperazinyl derivatives as modulators of chemokine receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperazinyl derivatives as modulators of chemokine receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinyl derivatives as modulators of chemokine receptor... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4107520

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.